CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Carboplatin +3 moredrug
Likely dose
Thiotepa 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00429182
NCT00429182Phase 2Completed
CompareCT.gov

Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients

M.D. Anderson Cancer Center·interventional·Posted Jan 31, 2007·Updated Apr 10, 2013

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Cyclophosphamide, and 2 other interventions for Breast Cancer and 2 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2007
Enrollment StartJun 1, 2007
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 19.4 years ago

Interventions

Carboplatindrug

Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.

Cyclophosphamidedrug

1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.

Thiotepadrug

120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.

Stem Cell Transplantprocedure

Stem Cell Transplant on Day 0.